Showing results (621-630 of 1,877) with videos related to

Sort By:
Pageof 188
Immunotherapy|May 17, 2023
Plain Language Summary of principles for improving the care of people with eosinophil-associated diseasesDavid J Jackson, Praveen Akuthota, Rebeca Andradas, et al.
Immunotherapy|May 17, 2023
Upadacitinib for moderate to severe atopic dermatitisFrancisco Navarro-Triviño, Sara Alcantara-Luna, Javier Domínguez-Cruz, et al.
Immunotherapy|May 16, 2023
Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumabSatoru Taguchi, Taketo Kawai, Sebastiano Buti, et al.
Immunotherapy|May 16, 2023
Association of circadian timing of initial infusions of immune checkpoint inhibitors with survival in advanced melanomaCynthia Yeung, Adi Kartolo, Justin Tong, et al.
Immunotherapy|July 9, 2020
Adoptive Treg cell-based immunotherapy: Frontier therapeutic aspects in rheumatoid arthritisMahdi Zavvar, Sara Assadiasl, Sina Zargaran, et al.
Immunotherapy|July 24, 2020
Neem leaf glycoprotein reverses tumor-induced and age-associated thymic involution to maintain peripheral CD8+ T cell poolIpsita Guha, Avishek Bhuniya, Partha Nandi, et al.
Immunotherapy|July 3, 2020
Antiprogrammed cell death protein 1 immunotherapy for angiosarcoma with high programmed death-ligand 1 expression: a case reportFei Xu, Jing Zheng, Mengjiao Fu, et al.
Immunotherapy|July 21, 2020
Mechanism of acquired resistance to nivolumab in lung squamous cell carcinoma: case report and review of the literatureLinying Wu, Yuman Yu, Jianying Zhou, et al.
Immunotherapy|March 26, 2015
The inflammasome and IL-1β: implications for the treatment of inflammatory diseasesTakashi Satoh, Atsushi Otsuka, Emmanuel Contassot, et al.
Immunotherapy|August 20, 2020
Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced NSCLCJiahao Li, Tiantian Zhang, Yongmei Xu, et al.
Pageof 188